Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Neuropharmacology. 2016 Jun 5;112(Pt A):150–163. doi: 10.1016/j.neuropharm.2016.06.005

Figure 3.

Figure 3

Ambulatory (top panels), non-ambulatory (middle panels) and vertical (bottom panels) activity measured over the two-hour test period during the training phase after the first (left panels) and the third (right panels) VM microinjections of vehicle (VEH, n = 22), 1.5 nmol of D-Tyr[11]Neurotensin (NT, n = 23), 40 pmol of CPP + NT (CPP40 + NT, n = 6), 120 pmol of CPP + NT (CPP120 + NT, n = 18), 40 pmol (CPP40, n = 8) or 120 of CPP (CPP120, n = 16) alone. Each bar represents the group mean ± s.e.m. Symbols indicate a statistically significant difference with respective VEH (*p < 0.05; **p < 0.01; ***p < 0.001) with respective NT group (+p < 0.05; +++p < 0.001) or between the first and the third injections for the corresponding treatment group (#p < 0.05; ##p < 0.01; ###p < 0.001). See method section for details.

HHS Vulnerability Disclosure